Tags

Type your tag names separated by a space and hit enter

Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin.
Diabetes Ther 2019; 10(5):1793-1800DT

Abstract

Attenuating postprandial hyperglycaemia is a critical factor in the achievement of optimal glucose control. Prandial insulin analogues have been developed to replicate the physiology of normal endogenous insulin secretion and action, with the aim of limiting postprandial glucose excursions. There is still, however, a significant unmet need, with many people failing to achieve desired glycaemic control targets despite the current armamentarium of prandial insulin analogues. Such insulins have a delayed onset and a longer duration of action than endogenous insulin production. There has been considerable focus on attempts to accelerate the time-action profile of prandial exogenous insulin in order to produce a more physiological profile. One such approach is to modify the insulin formulation. Fast-acting insulin aspart is a modified formulation of insulin aspart containing niacinamide and L-arginine. It has an earlier onset of action than aspart. In an extensive trial programme, this faster aspart demonstrated similar HbA1c reductions to those achieved with aspart but superior postprandial glucose reductions, with no increase in hypoglycaemia. Furthermore, administration of faster aspart up to 20 min after the start of a meal permitted similar glucose control to aspart given preprandially. These data, taken in totality, illustrate the potential role of faster insulin aspart in clinical practice.

Authors+Show Affiliations

Department of Diabetes and Endocrinology, University Hospital Llandough, Penlan Road, Penarth, CF64 4XX, UK. Marclyndon1@hotmail.com.Department of Diabetes and Endocrinology, University Hospital Llandough, Penlan Road, Penarth, CF64 4XX, UK.Department of Diabetes and Endocrinology, University Hospital Llandough, Penlan Road, Penarth, CF64 4XX, UK.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31485918

Citation

Evans, Marc, et al. "Fast-Acting Insulin Aspart: the Rationale for a New Mealtime Insulin." Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, vol. 10, no. 5, 2019, pp. 1793-1800.
Evans M, Wilkinson M, Giannpolou A. Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin. Diabetes Ther. 2019;10(5):1793-1800.
Evans, M., Wilkinson, M., & Giannpolou, A. (2019). Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders, 10(5), pp. 1793-1800. doi:10.1007/s13300-019-00685-0.
Evans M, Wilkinson M, Giannpolou A. Fast-Acting Insulin Aspart: the Rationale for a New Mealtime Insulin. Diabetes Ther. 2019;10(5):1793-1800. PubMed PMID: 31485918.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin. AU - Evans,Marc, AU - Wilkinson,Mathew, AU - Giannpolou,Angeliki, Y1 - 2019/09/04/ PY - 2019/07/23/received PY - 2019/9/6/pubmed PY - 2019/9/6/medline PY - 2019/9/6/entrez KW - Diabetes KW - Faster insulin aspart KW - Insulin KW - Insulin aspart SP - 1793 EP - 1800 JF - Diabetes therapy : research, treatment and education of diabetes and related disorders JO - Diabetes Ther VL - 10 IS - 5 N2 - Attenuating postprandial hyperglycaemia is a critical factor in the achievement of optimal glucose control. Prandial insulin analogues have been developed to replicate the physiology of normal endogenous insulin secretion and action, with the aim of limiting postprandial glucose excursions. There is still, however, a significant unmet need, with many people failing to achieve desired glycaemic control targets despite the current armamentarium of prandial insulin analogues. Such insulins have a delayed onset and a longer duration of action than endogenous insulin production. There has been considerable focus on attempts to accelerate the time-action profile of prandial exogenous insulin in order to produce a more physiological profile. One such approach is to modify the insulin formulation. Fast-acting insulin aspart is a modified formulation of insulin aspart containing niacinamide and L-arginine. It has an earlier onset of action than aspart. In an extensive trial programme, this faster aspart demonstrated similar HbA1c reductions to those achieved with aspart but superior postprandial glucose reductions, with no increase in hypoglycaemia. Furthermore, administration of faster aspart up to 20 min after the start of a meal permitted similar glucose control to aspart given preprandially. These data, taken in totality, illustrate the potential role of faster insulin aspart in clinical practice. SN - 1869-6953 UR - https://www.unboundmedicine.com/medline/citation/31485918/Fast-Acting_Insulin_Aspart:_The_Rationale_for_a_New_Mealtime_Insulin L2 - https://dx.doi.org/10.1007/s13300-019-00685-0 DB - PRIME DP - Unbound Medicine ER -